The majority of women living with HIV are of childbearing age and many of these women wish to have a family. As a result of advances in the treatment and management of HIV, more reproductive opportunities are now available to this group. However, women living with HIV may still require education and guidance in a range of reproductive situations, including avoiding pregnancy, seeking fertility treatment or having a child. HIV physicians should be aware of recent data and guidance on these situations – including areas where more data are required – and consider them when deciding on appropriate management for their patients.
VolminkJ., SiegfriedN.L., van der MerweL., BrocklehurstP.Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev2007; CD003510.
HeikinheimoO., LahteenmakiP.Contraception and HIV infection in women. Hum Reprod Update2009; 15: 165–176.
6.
MitchellH.S., StephensE.Contraception choice for HIV positive women. Sex Transm Infect2004; 80: 167–173.
7.
HeardI., SittaR., LertF.Reproductive choice in men and women living with HIV: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA Study). AIDS2007; 21Suppl 1: S77–S82.
8.
CliffeS., TownsendC.L., Cortina-BorjaM., NewellM.L.Fertility intentions of HIV-infected women in the United Kingdom. AIDS Care2011; 23: 1093–1101.
9.
SempriniA.E., HollanderL.H., VucetichA., Gilling-SmithC.Infertility treatment for HIV-positive women. Womens Health (Lond Engl)2008; 4: 369–382.
NostlingerC., NiderostS., WooR., PlatteauT., LoosJ., ColebundersR.Mirror, mirror on the wall: the face of HIV + women in Europe today. AIDS Care2010; 22: 919–926.
15.
De VincenziI., JadandC., CouturierE.Pregnancy and contraception in a French cohort of HIV-infected women. SEROCO Study Group. AIDS1997; 11: 333–338.
16.
WilsonT.E., MassadL.S., RiesterK.A.Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: results from the Women's Interagency HIV Study. AIDS1999; 13: 591–598.
17.
FioreS., HeardI., ThorneC.Reproductive experience of HIV-infected women living in Europe. Hum Reprod2008; 23: 2140–2144.
18.
FloridiaM., TamburriniE., RavizzaM.Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther2006; 11: 941–946.
19.
SaxtonJ., MalyutaR., SemenenkoI.Previous reproductive history and post-natal family planning among HIV-infected women in Ukraine. Hum Reprod2010; 25: 2366–2373.
20.
MinnisA.M., PadianN.S.Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect2005; 81: 193–200.
21.
MartinH.L.Jr., NyangeP.M., RichardsonB.A.Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis1998; 178: 1053–1059.
22.
KapigaS.H., LyamuyaE.F., LwihulaG.K., HunterD.J.The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS1998; 12: 75–84.
23.
HeffronR., DonnellD., ReesH.Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis2012; 12: 19–26.
24.
RichardsonB.A., OtienoP.A., Mbori-NgachaD., OverbaughJ., FarquharC., John-StewartG.C.Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS2007; 21: 749–753.
25.
MorrisonC.S., ChenP.L., NankyaI.Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr2011; 57: 157–164.
26.
KiddugavuM., MakumbiF., WawerM.J.Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS2003; 17: 233–240.
27.
KleinschmidtI., ReesH., DelanyS.Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception2007; 75: 461–467.
28.
MorrisonC.S., Skoler-KarpoffS., KwokC.Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS2012; 26: 497–504.
29.
PolisC.B., CurtisK.M.Hormonal contraception and HIV acquisition in women: a systematic review of the epidemiological evidence.XIX International AIDS Conference. 22–27 July 2012, Washington, DC, USA. Abstract WEAC0203.
CDC.Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use. 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep2012; 61: 449–452.
32.
RobinsonJ.A., JamshidiR., BurkeA.E.Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstet Gynecol2012; 2012: 890160.
33.
WatersL., BartonS.Contraception and HIV: what do we know and what needs to be done?J Fam Plann Reprod Health Care2006; 32: 10–14.
FakoyaA., LambaH., MackieN.British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. HIV Med2008; 9: 681–720.
BungenerC., Marchand-GonodN., JouventR.African and European HIV-positive women: psychological and psychosocial differences. AIDS Care2000; 12: 541–548.
38.
DoyalL.Challenges in researching life with HIV/AIDS: an intersectional analysis of black African migrants in London. Cult Health Sex2009; 11: 173–188.
39.
ThomasF., AggletonP., AndersonJ.'If I cannot access services, then there is no reason for me to test': the impacts of health service charges on HIV testing and treatment amongst migrants in England. AIDS Care2010; 22: 526–531.
40.
BouhnikA.D., PréauM., LertF.Unsafe sex in regular partnerships among heterosexual persons living with HIV: evidence from a large representative sample of individuals attending outpatients services in France (ANRS-EN12-VESPA Study). AIDS2007; 21Suppl 1: S57–S62.
41.
StevensP.E., GalvaoL.'He won't use condoms': HIV-infected women's struggles in primary relationships with serodiscordant partners. Am J Public Health2007; 97: 1015–1022.
42.
ClarkR.A., KissingerP., BedimoA.L., DunnP., AlbertinH.Determination of factors associated with condom use among women infected with human immunodeficiency virus. Int J STD AIDS1997; 8: 229–233.
43.
DiazT., SchableB., ChuS.Y.Relationship between use of condoms and other forms of contraception among human immunodeficiency virus-infected women. Supplement to HIV and AIDS Surveillance Project Group. Obstet Gynecol1995; 86: 277–282.
44.
CarrieriM.P., ReyD., SerrainoD.Oral contraception and unprotected sex with occasional partners of women HIV-infected through injection drug use. AIDS Care2006; 18: 795–800.
45.
FloridiaM., TamburriniE., TibaldiC.Voluntary pregnancy termination among women with HIV in the HAART era (2002–2008): a case series from a national study. AIDS Care2010; 22: 50–53.
46.
Desgrées-Du-LoÛA., MsellatiP., VihoI.Contraceptive use, protected sexual intercourse and incidence of pregnancies among African HIV-infected women. DITRAME ANRS 049 Project, Abidjan 1995–2000. Int J STD AIDS2002; 13: 462–468.
47.
AmmassariA., CicconiP., LadisaN.Induced first abortion rates before and after HIV diagnosis: results of an Italian self-administered questionnaire survey carried out in 585 women living with HIV. HIV Med2013; 14: 31–39.
48.
CrankshawT.L., MatthewsT.L., GiddyJ.A conceptual framework for understanding HIV risk behaviour in the context of supporting fertility goals among HIV-serodiscordant couples. Reprod Health Matters2012; 20: 50–60.
49.
Gilling-SmithC., NicopoullosJ.D., SempriniA.E., FrodshamL.C.HIV and reproductive care – a review of current practice. BJOG2006; 113: 869–878.
50.
CohenM.S., ChenY.Q., McCauleyM.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med2011; 365: 493–505.
51.
BaetenJ.M., DonnellD., NdaseP.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med2012; 367: 399–410.
52.
HuntingtonS.E., BansiL.K., ThorneC.Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. AIDS2011; 25: 1647–1655.
53.
AsanderA.S., BjorkmanA., BelfrageE., FaxelidE.HIV-infected African parents living in Stockholm, Sweden: disclosure and planning for their children's future. Health Soc Work2009; 34: 107–115.
54.
FrodshamL.C., BoagF., BartonS., Gilling-SmithC.Human immunodeficiency virus infection and fertility care in the United Kingdom: demand and supply. Fertil Steril2006; 85: 285–289.
55.
CollO., LopezM., VidalR.Fertility assessment in non-infertile HIV-infected women and their partners. Reprod Biomed Online2007; 14: 488–494.
56.
GrayG.E., McIntyreJ.A.Effect of HIV on women. AIDS Read2006; 16: 365–368.
57.
BujanL., HollanderL., CoudertM.Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network. AIDS2007; 21: 1909–1914.
58.
Centres for Reproductive Assistance Techniques to HIV Couples in Europe (CREAThE).Retrospective evaluation of the outcome of infertility treatment in HIV positive women 2012. (Accessed 17 April 2013.) Available from http://www.creathe.org/index.php?id=11&language=english&menu=4.
59.
Centres for Reproductive Assistance Techniques to HIV Couples in Europe (CREAThE).SHARE (Studying HIV and Reproduction in Europe) registry of reproductive assistance to couples with HIV 2012. (Accessed 17 April 2013.) Available from http://www.creathe.org/index.php?id=11&language=english&menu=4.
60.
GoutC., RougierN., OgerP.[Assisted reproductive technologies in HIV patients: a comprehensive review of indications, techniques and results]. Gynecol Obstet Fertil2011; 39: 704–708. French.
61.
DoyalL., AndersonJ.'My fear is to fall in love again…’ how HIV-positive African women survive in London. Soc Sci Med2005; 60: 1729–1738.
62.
FrenchC.E., Cortina-BorjaM., ThorneC., TookeyP.A.Incidence, patterns, and predictors of repeat pregnancies among HIV-infected women in the United Kingdom and Ireland, 1990–2009. J Acquir Immune Defic Syndr2012; 59: 287–293.
63.
WarszawskiJ., TubianaR., Le ChenadecJ.Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS2008; 22: 289–299.
64.
TownsendC.L., Cortina-BorjaM., PeckhamC.S., de RuiterA., LyallH., TookeyP.A.Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS2008; 22: 973–981.
65.
JohnsonM., AfoninaL., HaanyamaO.The challenges of testing for HIV in women: experience from the UK and other European countries. Antivir Ther2013; 18Suppl 2: 19–25.
66.
Aebi-PoppK., LapaireO., GlassT.R.Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003–2008. J Perinat Med2010; 38: 353–358.
67.
TariqS., ElfordJ., Cortina-BorjaM., TookeyP.A.The association between ethnicity and late presentation to antenatal care among pregnant women living with HIV in the UK and Ireland. AIDS Care2012; 24: 978–985.
68.
ThorneC., SemenenkoI., MalyutaR.Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000–10. Addiction2012; 107: 118–128.
Department of Health and Human Services.Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, 2011. (Accessed 11 October 2012.) Available from http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf.
NavérL., AlbertJ., BelfrageE.Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2010. Scand J Infect Dis2011; 43: 411–423.
73.
TaylorS., DaviesS.Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS2010; 5: 335–343.
FordN., CalmyA., MofensonL.Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS2011; 25: 2301–2304.
77.
European Collaborative Study.Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis2005; 40: 458–465.
78.
PrietoL.M., Gonzalez-TomeM.I., MunozE.Low rates of mother-to-child transmission of HIV-1 and risk factors for infection in Spain: 2000–2007. Pediatr Infect Dis J2012; 31: 1053–1058.
79.
TubianaR., Le ChenadecJ., RouziouxC.Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis2010; 50: 585–596.
80.
European Collaborative Study in EuroCoord.Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. Antivir Ther2011; 16: 895–903.
81.
BuckoreelallK., CresseyT.R., KingJ.R.Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet2012; 51: 639–659.
82.
StekA.M.Antiretroviral medications during pregnancy for therapy or prophylaxis. Curr HIV/AIDS Rep2009; 6: 68–76.
83.
Fayet-MelloA., BuclinT., GuignardN.Free and total plasma levels of lopinavir during pregnancy, at delivery and in postpartum: implication for dosage adjustments in pregnant women. Antivir Ther2012; doi: 10.3851/IMP2328.
84.
ConradieF., ZorrillaC., JosipovicD.Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med2011; 12: 570–579.
85.
ColbersA., MoltoJ., IvanovicJ.A comparison of the pharmacokinetics of darunavir, atazanavir and ritonavir during pregnancy and post-partum.19th Conference on Retroviruses and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA. Poster 1013.
86.
von HentigN., NisiusG., LennemannT.Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther2008; 13: 1039–1046.
87.
FangA., ValluriS.R., O'SullivanM.J.Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum. HIV Clin Trials2012; 13: 46–59.
88.
StekA.M., BestB.M., LuoW.Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med2012; 13: 226–235.
89.
CresseyT.R., StekA., CapparelliE.Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr2012; 59: 245–252.
90.
PrietoL.M., Gonzalez-TomeM.I., MunozE.Low rates of mother-to-child transmission of HIV-1 and risk factors for infection in Spain: 2000–2007. Pediatr Infect Dis J2012; 31: 1053–1058.
91.
KourtisA.P., SchmidC.H., JamiesonD.J., LauJ.Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS2007; 21: 607–615.
92.
PowisK.M., KitchD., OgwuA.Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis2011; 204: 506–514.
93.
KourtisA.P., FowlerM.G.Antiretroviral use during pregnancy and risk of preterm delivery: more questions than answers. J Infect Dis2011; 204: 493–494.
94.
SibiudeJ., WarszawskiJ., TubianaR.Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?Clin Infect Dis2012; 54: 1348–1360.
95.
BeckermanK., AlbanoJ., CohanD.Exposure to combination antiretroviral (cARV) regimens containing protease inhibitors (PI) during pregnancy and prevalence of low birth weight/preterm delivery (LBW/PTD) among women with low pre-existing risk for LBW/PTD: a stratified analysis of 10,082 prospective reports of live births in the Antiretroviral Pregnancy Registry (APR), 1989–2010.6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 17–20 July 2011, Rome, Italy. Poster TULBPE018.
96.
SamuelM., BradshawD., PerryM.Atazanavir in pregnancy: a retrospective review of 155 cases to assess tolerability, toxicity, efficacy and the proportion of exposed neonates delivered preterm.13th European AIDS Conference. 12–15 October 2011, Belgrade, Serbia. Abstract PE14.9/1.
97.
AzriaE., MoutafoffC., SchmitzT.Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antivir Ther2009; 14: 423–432.
98.
LopezM., FiguerasF., HernandezS.Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. AIDS2012; 26: 37–43.
PatelD., ThorneC., FioreS., NewellM.L.Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women?J Acquir Immune Defic Syndr2005; 40: 116–118.
101.
TownsendC.L., WilleyB.A., Cortina-BorjaM., PeckhamC.S., TookeyP.A.Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. AIDS2009; 23: 519–524.
102.
FrenchC.E., ThorneC.N., Cortina-BorjaM., TookeyP.A.Repeat pregnancies among HIV-infected women: immunologic status and virologic outcomes among those not on antiretroviral therapy at conception.19th Conference on Retroviruses and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA. Poster 1019.
103.
World Health Organization.Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Recommendations for a public health approach (2010 version). (Accessed 17 April 2013.) Available from http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html.
104.
TaylorG.P., ClaydenP., DharJ.British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med2012; 13Suppl 2: 87–157.
LindegrenM.L., KennedyC.E., Bain-BrickleyD.Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and family planning services. Cochrane Database Syst Rev2012; 9: CD010119.
